NCT03619005 - Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study | Biotech Hunter

Timeline

Start Date

November 13, 2018

Primary Completion Date

August 15, 2019

Study Completion Date

December 6, 2019

Conditions

Hypoactive Sexual Desire Disorder (HSDD)

Interventions

DRUG

Placebo Vaginal Insert

Daily administration of a placebo vaginal insert.

DRUG

Prasterone 6.5 mg (0.50%) Vaginal Insert

Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.

Trial Locations (10)

Endoceutics site # 20, New York

Endoceutics site # 127, Bluffton

Endoceutics site # 119, Roswell

Endoceutics site # 91, Savannah

Endoceutics site # 114, St. Petersburg

Endoceutics site # 106, Huntsville

Endoceutics site # 115, Fargo

Endoceutics site # 102, San Antonio

Endoceutics site # 17, San Diego

Endoceutics site # 125, New London